Preoperative chemoradiotherapy for esophageal cancer: Factors associated with clinical response and postoperative complications

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2555-2562

  Morita, Masaru ^a   Masuda, Takanobu ^a   Okada, Satoko ^a   Yoshinaga, Keiji ^a   Saeki, Hiroshi ^a   Tokunaga, Eriko ^a   Endo, Kazuya ^a   Emi, Yasunori ^a   Kakeji, Yoshihiro ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Morbidity; Mortality; Preoperative chemoradiotherapy; Prognosis

Indexed keywords

BLEOMYCIN; CISPLATIN; FLUOROURACIL;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 69249194750     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Earlam R and Cunha-Melo JR: Oesophageal squamous cell carcinoma: a critical review of surgery. Br J Surg 67: 381-390, 1980. (Pubitemid 10059625)
2. Muller JM, Erasmi H, Stelzner M, Zieren U and Pichlmaier H: Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-857, 1990.
3. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000. (Pubitemid 30616724)
4. Tsurumaru M, Kajiyama Y, Udagawa H and Akiyama H: Outcomes of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus. Ann Thorac Cardiovasc Surg 7: 325-329, 2001.
5. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, Leyn PD, Van Raemdonck D and Ectors N: Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: Impact on staging, disease-free survival, and outcome. Ann Surg 240: 962-972, 2004.
6. Morita M, Yoshida R, Ikeda K, Egashira A, Oki E, Sadanaga N, Kakeji Y, Yamanaka T and Maehara Y: Advances in esophageal cancer surgery in Japan: An analysis of 1,000 consecutive patients treated at a single institute. Surgery 143: 499-508, 2008.
7. Hofstetter W, Swisher GS, Correa AM, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-385, 2002. (Pubitemid 34971347)
8. Bosset JF, Gingnoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemotheapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997. (Pubitemid 27306287)
9. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncology 8: 226-234, 2007. (Pubitemid 46291702)
10. Fiorica F, DiBona D, Schepis F, Licata A, Schahid L, Venturi A, Falchi AM, Craxì A and Cammà C: Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53: 925-930, 2004. (Pubitemid 38824146)
11. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET and Denham JW, Trans-Tasman Radiation Oncology Group, Australasian Gastro-Intestinal Trials Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomized controlled phase III trial. Lancet Oncology 6: 659-668, 2005.
12. Urba S, Orringer M, Turrisi A Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001. (Pubitemid 32112841)
13. Greer SE, Goodney PP, Sutton JE and Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 137: 172-177, 2005. (Pubitemid 40174424)
14. Avendano CE, Flume PA, Silvesri GA, King LB and Reed CE: Pulmonary complications after esophagectomy. Ann Thorac Surg 73: 922-926, 2002.
15. Fink U, Stein HJ and Wilke H: Multimodal treatment for squamous cell esophageal cancer. World J Surg 19: 198-204, 1995.
16. Law S, Wong K, Kwak K, Chu K and Wong J: Predictive factors for postoperateive pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 240: 791-800, 2004. (Pubitemid 39425771)
17. Kelley ST, Coppola D and Karl RC: Neoadjuvant chemoradiotherapy is not associated with a higher complication rate vs. surgery alone in patients undergoing esophagectomy. J Gastrointest Surg 8: 227-232, 2004. (Pubitemid 38344154)
18. Lin FC, Durkin AE and Ferguson MK: Induction therapy does not increase surgical morbidity after esophagectomy for cancer. Ann Thorac Surg 78: 1783-1789, 2004.
19. Mandard AM, Dalibaard F, Mandard JC, Marnay J, Henry-AQrmar M, Petiot JF, Roussel A, Jacob JH, Segol P and Samama G: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcimoma. Cancer 73: 2680-2686, 1994.
20. Rohatgi PR, Swisher SG, Correa A, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA and Ajani JA: Failure correlate with the proportion of residual carcinoma after preoperative chemotherapy for carcinoma of the esophagus. Cancer 104: 1349-1355, 2005. (Pubitemid 41356149)
21. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL and Roth JA: Proposed revision of the esophageal cancer staging system accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 241: 810-820, 2005.
22. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H and Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23: 4330-4337, 2005. (Pubitemid 46207006)
23. Saeki H, Kawaguchi H, Kitamura K, Ohno S and Sugimachi K: Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. J Surg Oncol 69: 224-229, 1998. (Pubitemid 29024566)
24. UICC International Union Against Cancer: TNM classification of Malignant Tumors (6th Edition).
25. Japanese Society for Esophageal Disease: Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part II. Esophagus 1: 107-125, 2004.
26. Altman DG: Practical Statistics for Medical Research. London Chapman & Hill, pp. 371-375, 1991.
27. Herskovic A, Martz K, Al-Sarrar M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593-1598, 1992.
28. Bessell JR, Devitt PG, Gill PG, Goyal S and Jamieson GG: Prolonged survival follows resection of esophageal SCC downstaged by prior chemoradiotheapy. Aust NZ J Surg 66: 214-217, 1996. (Pubitemid 26124483)
29. Geh JI, Bond SJ, Bentzen S and Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiother Oncol 78: 236-244, 2006.
30. Tsutsui S, Morita M, Kuwano H, Kuwano H, Matsuda H, Mori M, Okamura S and Sugimachi K: Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma. J Surg Oncol 49: 176-181, 1992.
31. Heidecke CD, Weighardt H, Feith M, Fink U, Zimmermann F, Strein HJ, Siewert JR and Holzmann B: Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy. Surgery 132: 495-501, 2002. (Pubitemid 35155484)
32. Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T and Blackstock AW: Predictive value of 18-fluorodeoxy-glucose positron-emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 243: 472-478, 2006.
33. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki R, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J and Roth JA: Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol 99: 1258-1266, 2004. (Pubitemid 39062261)
34. Luthra R, Wu T, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG and Ajani JA: Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol 24: 259-267, 2006. (Pubitemid 46628468)
35. Ishida M, Morita M Ishida M, Saeki H, Ohga T, Sadanaga N, Watanabe M, Kakeji Y and Maehara Y: Expression of p53 and p21 and clinical response for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Anticancer Res 27: 3501-3506, 2007. (Pubitemid 47607493)
36. Baumann M and Krause M: EGFR-targeted anticancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83: 238-248, 2007. (Pubitemid 46915540)